Alimta

... Drug companies refuse lower pricing on four medicines - National - smh.com.au NEWS register Drug companies refuse lower pricing on four medicines By Mark Metherell Political CorrespondentJune 16, 2005 Page Tools Email to a friend Printer format Patients face significantly higher costs for four prescribed medicines, including an expensive cancer treatment, after a revolt by drug companies against a Federal Government demand for lower prices.

The Health Minister, Tony Abbott, disclosed last night that patients will pay a "special patient contribution" over and above existing co-payments for four drugs.

The drugs are The patient contributions, on top of the $28.60 co-payment for general patients and $4.60 for health card holders, will take effect from August 1.

A spokeswoman for Mr Abbott refused to say how much patients would pay because she said the extra charges remained "commercial-in-confidence" until formally notified by the Pharmaceutical Benefits Scheme.

The announcement is a fresh setback for the Government's controversial measure, a...

... Research and Markets: More People Die of Lung Cancer Than of Colon, Breast, and Prostate Cancers Combined Research and Markets: More People Die of Lung Cancer Than of Colon, Breast, and Prostate Cancers Combined DUBLIN, Ireland, June 9 /PRNewswire/ - Research and Markets (http://www.researchandmarkets.com/reports/c18898 ) has announced the addition of Lung Cancer Outlook to their offering.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040820/RESEARCH ) Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world.

According to American Cancer Society predictions, 173,770 will be diagnosed and 160,440 people will die by lung cancer in 2004.

In the year 2002, over 800,000 people worldwide died of non-small cell lung cancer (NSCLC).

More people die of lung cancer than of colon, breast, and prostate cancers combined.

This issue of Cancer Highlights studies the progress of the most pronounced anti-cancer drugs in development for the treatment of NSCLC.

Several unfavorable results have been the reality for many drugs.

But, in contrary Eli Lilly's More than 200 companies have been identified that have, or have had, drugs under therapeutic development in patients with lung cancer in one form or the other.

Of these, approximately 30 companies are conducting phase III trials for lung cancer.

These late stage investigational drugs are the most discussed drugs durin...

... webnewswire.com - Former Employee of the Year at Eli Lilly and Company Accepts Position at Nanovir Last Updated: June 9, 2005, 7:59 am Subscribe Submit News Search News Subscribers About us Feedback Sections · Automobiles· Business· Crime· Culture· Defence· Education· Fashion· Finance· Health· International· IT· Entertainment· Jobs· Lifestyle· Marketing· News· Nature· Politics· Sports· Spirituality· Technology· Telecom· Terrorism· Tourism· Women Ads Former Employee of the Year at Eli Lilly and Company Accepts Position at NanovirDr.

Krishna Menon, VMD, MRCS, PhD., Co-Inventor of Two "Blockbuster Drugs" Having Nearly a Billion Dollars in Annual Sales EDot.com, Inc.

(Nanoviricides) (Pink Sheets:ECMM), announced that Dr.

Krishna Menon accepted the position of Chief Regulatory officer.

Dr.

Menon is a former "Employee of the Year" and "President's Award" winner at Eli Lilly, having led several blockbuster drug projects there.

"I'm very excited at the prospect of joining Nanoviricides," Dr.

Menon noted.

"This technology represents, in my opinion, a market leading concept.

It allows for a textbook finish for so many well conceived APIs, allowing delivery to target cells with lowest dosage, which increases efficacy and reduces toxicity." Dr.

Menon further noted, "This concept was completely unimaginable just a short while ago.

Many of the leading pharmaceutical companies now know how important this nano technology is, but still are unce...